MAG
GILD icon

Meadowbrook Advisors Group’s Gilead Sciences GILD Stock Holding History

Meadowbrook Advisors Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Sell
2,184
-318
-13% -$41.9K 0.15% 141
2026
Q1 		$349K Buy
2,502
+42
+2% +$5.88K 0.21% 101
2025
Q4 		$302K Buy
+2,460
New +$299K 0.17% 110

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Meadowbrook Advisors Group's GILD Position: Q2 2026 in Review

Meadowbrook Advisors Group reduced its Gilead Sciences (GILD) stake by 13% in Q2 2026, selling an estimated $41.9K and leaving 2,184 shares worth $276K. The position accounts for 0.15% of the portfolio, ranked #141.

Meadowbrook Advisors Group first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $349K in Q1 2026. 2,264 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Meadowbrook Advisors Group held 2,184 shares of Gilead Sciences worth $276K as of Q2 2026.
  • Meadowbrook Advisors Group sold 318 Gilead Sciences shares in Q2 2026, an estimated $41.9K.
  • Gilead Sciences made up 0.15% of Meadowbrook Advisors Group's portfolio in Q2 2026, its #141 holding.
  • Meadowbrook Advisors Group first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Meadowbrook Advisors Group's Gilead Sciences position peaked at $349K in Q1 2026.
  • 2,264 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Meadowbrook Advisors Group's 13F filing for Q2 2026, filed 7 Aug 2026.